<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063164</url>
  </required_header>
  <id_info>
    <org_study_id>33356</org_study_id>
    <nct_id>NCT03063164</nct_id>
  </id_info>
  <brief_title>A Comparison of LASIK Outcomes Using Two Femtosecond Lasers</brief_title>
  <official_title>A Prospective, Randomized, Fellow Eye Comparison of Fellow Eyes Undergoing LASIK With the Intralase IFS150 Versus the Visumax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward E. Manche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing LASIK outcomes using two femtosecond lasers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will have a comprehensive eye examination once they express an interest in the&#xD;
      study. This includes a slit lamp examination of the front of the eye and a dilated&#xD;
      fundoscopic examination of the back of the eye. If there is any pathology noted that would&#xD;
      exclude the patient from the study, then the investigator will inform the patient and make an&#xD;
      appropriate referral. Patients deemed appropriate for the study after a comprehensive&#xD;
      examination including computerized videokeratography can be enrolled. Patients will undergo&#xD;
      bilateral simultaneous eye surgery. Which eye is treated with the Intralase IFS 150 and which&#xD;
      eye is treated with VisuMax will be randomized so there is a 50% chance for either eye to&#xD;
      receive one treatment. Patients will be seen on the day of surgery, post op day one, one&#xD;
      month, three months, six months and one year. Patients will receive topical antibiotics in&#xD;
      each eye for one week following the procedure. Patients will receive pred forte 1% ophthalmic&#xD;
      drops for one week after treatment. Patients will also receive vigamox ophthalmic drops for&#xD;
      four days after treatment. All of this is within the usual and customary standard of care for&#xD;
      the treatment of patients undergoing LASIK surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eye to eye comparison</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ETDRS Uncorrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>ETDRS testing charts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anterior segment ocular coherence tomography measurement of flap thickness</measure>
    <time_frame>One month</time_frame>
    <description>Anterior segment ocular coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cochet Bonnet Asthesiometry measurement of corneal sensation</measure>
    <time_frame>One, three, six and twelve months</time_frame>
    <description>Cochet Bonnet Asthesiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best spectacle corrected visual acuity</measure>
    <time_frame>One, three, six and twelve months</time_frame>
    <description>ETDRS testing charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrometry</measure>
    <time_frame>One three, six and twelve months</time_frame>
    <description>Aberrometry images will be obtained on the iDesign aberrometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire measuring patient preference for laser device</measure>
    <time_frame>Intraoperative, one, three, six and twelve months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes with LASIK</measure>
    <time_frame>One month, three months, six months and twelve months</time_frame>
    <description>PROWL study questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Intralase IFS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intralase IFS vs. Visumax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Visumax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Visumax vs. Intralase iFS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intralase IFS150</intervention_name>
    <description>Intralase flap creation</description>
    <arm_group_label>Intralase IFS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Visumax</intervention_name>
    <description>Visumax flap creation</description>
    <arm_group_label>Visumax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects age 21 and older with healthy eyes. Nearsightedness between -0.25 diopters&#xD;
             and -11.00 diopters with or without astigmatism of up to 5.00 diopters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects under the age of 21&#xD;
&#xD;
          -  Subjects over the age of 60&#xD;
&#xD;
          -  Subjects with corneal ectatic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Manche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 11, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Edward E. Manche</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Femtosecond laser</keyword>
  <keyword>Visumax</keyword>
  <keyword>Intralase IFS150</keyword>
  <keyword>LASIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 15, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

